Evidence map›Paper›PMID 40524228›Full record

ArticleBreast cancer research : BCR2025

Axillary adipose tissue-derived lymphatic endothelial cells exhibit distinct transcriptomic signatures reflecting lymphatic invasion status in breast cancer.

Asumi Iesato, Jun Suzuka, Kazutaka Otsuji, Tomo Osako, Nami Yamashita, Yuka Inoue, Tetsuyo Maeda, Natsue Uehiro, Kazuyo Yoshida, Yoko Takahashi and 11 more

Abstract read
In one paragraph

Article in Breast cancer research : BCR, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Asumi IesatoNEXT-Ganken Program, Cancer Cell Diversity Project, Japanese Foundation for Cancer Research, Tokyo, Japan.
Jun SuzukaNEXT-Ganken Program, Cancer Cell Diversity Project, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazutaka OtsujiNEXT-Ganken Program, Cancer Cell Diversity Project, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tomo OsakoDivision of Pathology, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Nami YamashitaBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yuka InoueBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuyo MaedaBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Natsue UehiroBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kazuyo YoshidaBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Yoko TakahashiBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Kohei KumegawaNEXT-Ganken Program, Cancer Cell Diversity Project, Japanese Foundation for Cancer Research, Tokyo, Japan.
Sumito SaekiDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31Koto-Ku, AriakeTokyo, 135-8550, Japan.
Liying YangDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31Koto-Ku, AriakeTokyo, 135-8550, Japan.
Ai TsuchiyaDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31Koto-Ku, AriakeTokyo, 135-8550, Japan.
Kana SakiyamaDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31Koto-Ku, AriakeTokyo, 135-8550, Japan.
Miwa TanakaDivision of Cancer Epigenomics, Cancer Institute, Japanese Foundation for Cancer Research, 3-8-31Koto-Ku, AriakeTokyo, 135-8550, Japan.
Takehiko SakaiBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Shinji OhnoBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Tetsuo NodaDirector's Room, Cancer Institute, Japanese Foundation for Cancer Research, Tokyo, Japan.
Takayuki UenoBreast Surgical Oncology, Breast Oncology Center, Cancer Institute Hospital, Japanese Foundation for Cancer Research, Tokyo, Japan.
Reo MaruyamaNEXT-Ganken Program, Cancer Cell Diversity Project, Japanese Foundation for Cancer Research, Tokyo, Japan. reo.maruyama@jfcr.or.jp.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundLymphatics provide a route for breast cancer cells to metastasize. Lymphatic endothelial cells (LECs), which form the structure of lymphatic vessels, play a key role in this process. Although LECs are pivotal in cancer progression, studies often rely on commercially available cell lines that may not accurately reflect the tumor microenvironment. Therefore, there is a pressing need to directly study patient-derived LECs to better understand their role in breast cancer.

methodsThis study developed a method to isolate and characterize LECs directly from human breast-to-axilla adipose tissue. We used magnetic cell separation to remove CD45 + leukocytes and fluorescence-activated cell sorting to isolate cells expressing CD31 and podoplanin. Isolated cells were cultured under conditions promoting endothelial cell growth and were characterized through various assays assessing proliferation, tube formation, and gene expression patterns.

resultsThe sorted CD31 + /PDPN + /CD45 - cell populations exhibited marked increases in proliferation upon VEGF-C stimulation and formed tubule structures on BME-coated dishes, confirming their LEC properties. Notably, isolated LECs showed distinct gene expression patterns depending on the presence of lymph node metastasis and lymphatic invasion.

conclusionsThe ability to isolate and characterize patient-derived LECs from mammary adipose tissue offers new insights into the cellular mechanisms underlying breast cancer metastasis. Significant gene expression variability related to disease state highlights the potential of these cells as biomarkers and therapeutic targets. This study emphasizes the importance of using patient-derived cells to accurately assess the tumor microenvironment, potentially leading to more personalized therapeutic approaches.

Indexed as

Adipose TissueBreast NeoplasmsEndothelial CellsTranscriptomeAxillaCell ProliferationFemaleGene Expression ProfilingGene Expression Regulation, NeoplasticHumansLeukocyte Common AntigensLymphangiogenesisLymphatic MetastasisLymphatic VesselsPlatelet Endothelial Cell Adhesion Molecule-1PodoplaninLeukocyte Common AntigensPDPN protein, humanPECAM1 protein, humanPlatelet Endothelial Cell Adhesion Molecule-1PodoplaninBreast cancerCell isolationGene expression analysisLymphatic endothelial cellsLymphatic invasion

Identifiers

PMID40524228
PMCPMC12172209

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.